Advances in the Diagnosis, Pathogenesis, and Management of Fibromyalgia Syndrome PsychCast™
Fibromyalgia Syndrome: Approach to Management (52:36 Minutes)
Author: I. Jon Russell, MD, PhD
This is a 1 hour PsychCast™ podcast with an Internet component.
This CME Expert Review PsychCast™ is jointly sponsored by the Mount Sinai School of Medicine and MBL Communications.
Release Date: May 2008
Termination Date: May 31, 2010
Funding for this activity has been provided through an educational grant from Eli Lilly and Company and Pfizer Inc.
Faculty Affiliations and Disclosures:
Dr. Russell is associate professor of medicine and director of the University Clinical Research Center at the University of Texas Health Sciences Center in San Antonio, editor of the Journal of Musculoskeletal Pain, and emeritus founding president of the International MYOPAIN Society. Dr. Russell is a consultant to and on the advisory boards of Eli Lilly, Jazz, and Pfizer; is on the speaker’s bureaus of Ortho-McNeil and Pfizer; and receives research contract support from Eli Lilly, Jazz, Ortho-McNeil, and Pfizer. He is supported, in part, by the RGK Foundation of Austin Texas. This article references unlabeled or unapproved uses of duloxetine, pregabalin, and sodium oxybate.
Learning Objectives
- Recognize that successful management of the fibromyalgia syndrome is possible.
- Recall the components of a multimodal therapy for FMS through a simple acronym.
- Identify successful medications for fibromyalgia syndrome symptoms by name and mechanism of action.
- Predict which combinations of drugs might be successful based on drug mechanisms of action as well as the individual patient’s symptoms.
Target Audience: This activity is designed to meet the educational needs of psychiatrists.
Peer Reviewers:
Eric Hollander, MD, does not have an affiliation with or financial interest in any organization that might pose a conflict of interest. This activity has been peer-reviewed and approved by Eric Hollander, MD, Professor of Psychiatry and Chair at Mount Sinai School of Medicine. Review Date: February 15, 2008
Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Mount Sinai School of Medicine and MBL Communications, Inc. The Mount Sinai School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: The Mount Sinai School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Policy Statement: It is the policy of Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
Disclaimer: These are the opinions of the authors not of the sponsors or supporters. For more information, contact MBL Communications at cme@mblcommunications.com.
Minimum Hardware/Software Requirements
Macintosh: PowerPC processor, Mac OS 8.6, 9.0.4, 9.1, or Mac OS X, 64MB of RAM, 24MB of available hard-disk space, and Safari 1.x or 2.x.
Windows PC: Intel Pentium processor, Microsoft Windows 95 OSR 2.0, Windows 98 and 98 SE, Windows Millennium Edition, Windows NT 4.0 with Service Pack 5, Windows 2000, or Windows XP, 64MB of RAM, 24MB of available hard-disk space, and Internet Explorer 6.x and newer or Firefox 1.x and newer.
This CME Activity and Posttest information file is a PDF (Portable Document Format) document. To view this file, you will need Adobe Acrobat Reader, which is available free at www.adobe.com. Follow the instructions on that page to download and install the software.
Advances in the Diagnosis, Pathogenesis, and Management of Fibromyalgia Syndrome PsychCast™
Fibromyalgia Syndrome: Approach to Management (52:36 Minutes)
Author: I. Jon Russell, MD, PhD
Abstract
The management of fibromyalgia syndrome (FMS) has traditionally been multimodal and multidisciplinary, including education, physical modalities, and medication. In this article, an acronym is offered to help the clinician remember the important components of management. An improved understanding of the pathogenesis of FMS has allowed substantial refinements in its treatment. This is particularly true for medications that target specific symptom domains, allowing individualization of therapy. Since all FMS patients experience pain, there has been emphasis on that domain although medications are now available to address two or more domains with monotherapy. In addition, a logical basis is provided to help the clinician design strategic polypharmacy.
To receive credit for this activity: Listen to the PsychCast™, reflect on the material presented, and complete the online CME Posttest/Evaluation here or to submit the CME Posttest/Evaluation by mail or fax, download a PDF here. To obtain credit, you should score 70% or better. The estimated time to complete the PsychCast™ and the posttest and evaluation is 1 hour. Successful completion of the posttest and evaluation will allow you to claim credit and print a certificate.
Early submission of this posttest is encouraged: please submit by May 1, 2010 to be eligible for credit. If you have any questions, please e-mail cme@mblcommunications.com.
Read the extended CME supplement related to this PsychCast™ activity here
Supported by Eli Lilly and Company and Pfizer Inc. |
Subscribe |
Download |
|
|
|
|